AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) has announced that its Chief Executive Officer, Thomas K. Equels, will participate in a Virtual Investor CEO Connect segment on Wednesday, October 2, 2024, at 4:00 PM ET. The event will feature a brief presentation by Mr. Equels, followed by an interactive Q&A session.
Investors and interested parties can submit questions live during the event or pre-submit them via email to AIM@jtcir.com. A live video webcast of the presentation will be available on the Events page of the Company's website (aimimmuno.com). A webcast replay will be accessible for 90 days, starting two hours after the live presentation.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AIM gained 3.70%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET
OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will participate in a Virtual Investor CEO Connect segment on Wednesday, October 2, 2024 at 4:00 PM ET.
As part of the event, Mr. Equels will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event by emailing AIM@jtcir.com. Mr. Equels will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
FAQ
When is AIM ImmunoTech's CEO participating in the Virtual Investor CEO Connect segment?
How can investors submit questions for AIM ImmunoTech's CEO during the Virtual Investor event?
Where can I watch the live webcast of AIM ImmunoTech's Virtual Investor CEO Connect segment?
How long will the replay of AIM ImmunoTech's Virtual Investor CEO Connect segment be available?
